Cvadrocef (cefepime) 1g. intravenous vial №1

$29.95

Manufacturer: Ukraine

Purpose: Targets bacterial cell walls, treats severe infections like pneumonia.

SKU: MED57560 Category:

Description

Cvadrocef (cefepime) 1g. Intravenous Vial №1

Ingredients

Active ingredient: Cefepime
Inactive ingredients: to be added by the manufacturer

Dosage

Dosage: The usual adult dosage is 1g every 12 hours for most infections. Dosage adjustments may be required based on the severity of the infection and the patient’s renal function.

Indications

Cvadrocef (cefepime) is indicated for the treatment of moderate to severe infections caused by susceptible bacteria, including pneumonia, urinary tract infections, skin and soft tissue infections, and intra-abdominal infections.

Contraindications

Contraindications: Do not use Cvadrocef if the patient has a known allergy to cefepime or other cephalosporins.

Directions

Cvadrocef is administered by intravenous infusion over a period of 30 minutes to 2 hours. It is important to follow the healthcare provider’s instructions regarding the dosage and duration of treatment.

Scientific Evidence

Cefepime, the active ingredient in Cvadrocef, is a fourth-generation cephalosporin with broad-spectrum antibacterial activity. Studies have shown its efficacy in treating various bacterial infections, including those caused by multidrug-resistant organisms. Research published in the Journal of Antimicrobial Chemotherapy demonstrated the effectiveness of cefepime in treating nosocomial infections.

Additional Information

In clinical trials, Cvadrocef has shown comparable efficacy to other broad-spectrum antibiotics while demonstrating a favorable safety profile. It is important to monitor for any signs of allergic reactions or adverse effects during treatment with Cvadrocef.

Cefepime exerts its pharmacological effects by inhibiting bacterial cell wall synthesis, leading to bacterial cell death. It has a longer half-life compared to other cephalosporins, allowing for less frequent dosing and improved patient compliance.

Comparative studies have shown that cefepime is more effective against certain gram-negative bacteria compared to third-generation cephalosporins. Its ability to penetrate the central nervous system makes it a valuable option for treating infections of the central nervous system.